The Washington Post (4/28, Millman) reports in its “Wonkblog” that the hepatitis C drug Sovaldi [sofosbuvir] is simultaneously “being hailed as a potential breakthrough treatment” and “vexing insurers.” The former sentiment comes from its efficacy in treating a disease affecting roughly 3.2 million people in the United States. However, concerns come from the $84,000 price tag for a 12-week full course of treatment. Between 20% and 30% of people with hepatitis C are covered by Medicaid.
Bruce Japsen also discusses Sovaldi in Forbes (4/28).
No comments:
Post a Comment